See Today's Golden Star Stocks 🔥 Free for 7 Days See Today's Golden Star Stocks 🔥 Free for 7 Days
NASDAQ:PRQR

Proqr Therapeutics N.v Stock Predictions

etoro logo Buy PRQR
*Your capital is at risk
$1.70
-0.0300 (-1.73%)
At Close: Jul 13, 2026
Forecast Earnings Financials Insider Trading Signals Historical Prices Predictions News Profile
Currently predicting for Tue, 14 Jul 2026
PRQR Live board
Community Bull/Bear
Target Next close

Join the PRQR prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

PRQR Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in
Forecast Desk

3-Month Forecasts For PRQR

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

PRQR Predictions History

Predictor Target Session Target Price Accuracy
Community predictor Next session USD target Record locked
Ranked predictor Previous session Bullish/Bearish Score locked

See the prediction record

Register to view community history, predictor profiles, accuracy, scores, and your own prediction trail for PRQR.

Create free account Log in
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Log in or create a free account to view and request 66-session forecasts for PRQR.
  • Price path
  • Approved predictor
  • 3-month horizon
Create Free Account Log In To View Forecasts
ABOUT PROQR THERAPEUTICS N.V.
ProQR Therapeutics N.V
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in...
Read Full Profile Here
GOLDEN STAR
Ticker Change Signal Date
SRPT
$17.02
11.34% Jun 29
NMRK
$15.02
1.20% Jun 24
NESR
$25.07
14.16% Jun 23
CAG
$13.43
2.98% Jun 23
GIB
$66.69
0.555% Jun 12
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE